Fig. 4: Integration of Deepath-MSI into the clinical workflow for efficient MSI screening.

The diagram compares the current workflow, where all colorectal cancer cases (N = 2236) undergo IHC/PCR testing, with the proposed Deepath-MSI workflow. The proposed approach utilizes Deepath-MSI analysis of H&E slides for initial screening, directing only predicted MSI-H cases (N = 322, 14.4%) to confirmatory IHC/PCR. This potentially excludes approximately 90.7% of MSS patients from further testing, significantly reducing the burden of ancillary tests.